Dual-payload conjugates see CDK7 debut
The increasingly important field of dual-payload antibody drug conjugates has gained another contender with the newly announced collaboration between Lonza's Synaffix subsidiary and Qurient. The partnership aims to develop a dual-payload ADC combining Synaffix’s exatecan-based technology with Qurient’s CDK7 inhibitor mocaciclib, with the target for the ADC yet to be disclosed. For Synaffix, this deal adds to a growing list partnerships featuring its ADC platform, following earlier collaborations with companies such as Boehringer Ingelheim and Elevation Oncology. Meanwhile, Qurient, a South Korean company, will bring mocaciclib, which is separately in clinical testing in combination with Keytruda; mocaciclib will now be explored as an ADC payload. This approach is notable as, according to OncologyPipeline, no other company is using a CDK7 inhibitor as a dual payload ADC, and only one preclinical study has been published evaluating such an approach.
Synaffix's recent collaborations
| Partner | Comments | Date |
|---|---|---|
| Sotio | Up to 3 ADCs with Synaffix’s ADC technology – $740m biodollar value | Oct 2023 |
| Elevation | Global access to Synaffix’s ADC platform to develop a HER3 ADC – $368m biodollar value | Dec 2024 |
| Mitsubishi Tanabe | Access to Synaffix’s ADC technology to develop a single ADC | Jan 2025 |
| Boehringer Ingelheim | Access to Synaffix’s ADC technology to develop ADC – $1.3bn biodollar value | Jan 2025 |
Note: Lonza acquired Synaffix in Jun 2023. Source: OncologyPipeline.
1811
